- Home
- SGN vs SILO Comparison
SGN vs SILO Comparison
Compare SGN & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- SILO
- Stock Information
- Founded
- SGN 2019
- SILO 2010
- Country
- SGN United States
- SILO United States
- Employees
- SGN N/A
- SILO N/A
- Industry
- SGN
- SILO Apparel
- Sector
- SGN
- SILO Consumer Discretionary
- Exchange
- SGN Nasdaq
- SILO Nasdaq
- Market Cap
- SGN 3.8M
- SILO 4.5M
- IPO Year
- SGN 2023
- SILO N/A
- Fundamental
- Price
- SGN $1.04
- SILO $0.63
- Analyst Decision
- SGN
- SILO
- Analyst Count
- SGN 0
- SILO 0
- Target Price
- SGN N/A
- SILO N/A
- AVG Volume (30 Days)
- SGN 863.1K
- SILO 2.2M
- Earning Date
- SGN 08-18-2025
- SILO 08-12-2025
- Dividend Yield
- SGN N/A
- SILO N/A
- EPS Growth
- SGN N/A
- SILO N/A
- EPS
- SGN N/A
- SILO N/A
- Revenue
- SGN $529,282.00
- SILO $72,102.00
- Revenue This Year
- SGN N/A
- SILO $1.86
- Revenue Next Year
- SGN N/A
- SILO N/A
- P/E Ratio
- SGN N/A
- SILO N/A
- Revenue Growth
- SGN 8.42
- SILO N/A
- 52 Week Low
- SGN $0.44
- SILO $0.41
- 52 Week High
- SGN $36.70
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- SGN 49.29
- SILO 50.79
- Support Level
- SGN $1.01
- SILO $0.60
- Resistance Level
- SGN $1.35
- SILO $0.66
- Average True Range (ATR)
- SGN 0.15
- SILO 0.04
- MACD
- SGN -0.02
- SILO 0.01
- Stochastic Oscillator
- SGN 27.40
- SILO 68.79
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.